Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Actuate Therapeutics, Inc. filings document a clinical-stage oncology issuer with Nasdaq-listed common stock and emerging growth company status. Registration statements and capital-structure disclosures cover the company's common stock offering, security terms, and public-company reporting framework.
Actuate's 8-K and proxy filings record material events, Regulation FD clinical disclosures for elraglusib in metastatic pancreatic ductal adenocarcinoma, material agreements, shareholder voting matters, board composition, director elections, auditor ratification, governance matters, and risk-related disclosures tied to its biopharmaceutical development program.
Actuate Therapeutics, Inc. held its virtual Annual Meeting of Stockholders on May 21, 2026. Stockholders elected two Class II directors, Aaron G.L. Fletcher, Ph.D. and Jason Keyes, each to serve three-year terms ending at the 2029 Annual Meeting, continuing until their successors are elected and qualified.
Fletcher received 14,877,247 votes for and 1,883,025 withheld, with 1,871,309 broker non-votes. Keyes received 16,727,875 votes for and 32,397 withheld, with 1,871,309 broker non-votes. Stockholders also ratified Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 18,571,817 votes for, 50,023 against, and 9,741 abstentions.
ACTUATE THERAPEUTICS, INC. director Dan Zabrowski received a grant of stock options as part of his compensation. The grant covers 15,000 options for Common Stock at an exercise price of $2.42 per share. These options were granted on May 21, 2026 and will vest in full on the one-year anniversary of the grant date. After this award, he holds 15,000 derivative securities directly, with the options scheduled to expire on May 21, 2036.
ACTUATE THERAPEUTICS, INC. director and 10% owner Todd S. Thomson received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, vest in full on the one-year anniversary of the grant date, and expire on May 21, 2036. Certain funds managed by Kairos Venture Investments, LLC are entitled to an indirect economic interest in these options because Thomson serves on the board as their representative.
ACTUATE THERAPEUTICS, INC. director Roger Sawhney received a grant of stock options that give him the right to buy 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036.
All 15,000 options relate to common stock and were acquired as a compensation grant, not through an open-market purchase. According to the footnote, these options will vest in full on the first anniversary of the grant date, so they become exercisable after that time.
Actuate Therapeutics director Amy L. Ronneberg received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.42 per share and expire on May 21, 2036. According to the footnote, these options vest in full on the first anniversary of the grant date. Following this award, her reported derivative holdings from this grant total 15,000 options.
ACTUATE THERAPEUTICS, INC. director Jason A. Keyes received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the footnote, the options will vest in full on the first anniversary of the grant date, meaning Keyes must remain eligible through that date before the award is fully exercisable. Following this grant, his reported derivative holdings from this award total 15,000 stock options.
ACTUATE THERAPEUTICS, INC. director Martin H. Huber Jr. received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share and expire on May 21, 2036. According to the filing, these options will vest in full on the anniversary of the grant date. Following this award, the filing shows Huber holding 15,000 stock options directly.
ACTUATE THERAPEUTICS, INC. director and ten percent owner Aaron G.L. Fletcher received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, expire on May 21, 2036, and will vest in full on the first anniversary of the grant date. Following this grant, Fletcher holds 15,000 stock options directly.
Actuate Therapeutics reports a Q1 2026 net loss of $5,625,749, modestly improved from $6,317,024 a year earlier, as it advances lead cancer drug elraglusib. Research and development expenses were $2,565,244 and general and administrative costs were $3,140,712, both roughly stable to slightly lower year over year.
Cash and cash equivalents were $8,134,004 with working capital of $3,797,551, and management expects this to fund operations only into July 2026, leading to a conclusion of substantial doubt about continuing as a going concern. The company is relying on a $100M at-the-market facility and a separate $50M committed equity facility for future funding.
Clinically, updated Phase 2 data in metastatic pancreatic cancer showed median overall survival of 10.1 months for elraglusib plus standard therapy versus 7.2 months for control, with higher 12- and 24-month survival rates, supporting plans for an oral formulation and additional studies, subject to securing more capital.
Actuate Therapeutics filed an 8-K to share that the FDA has cleared an Investigational New Drug application for an oral tablet formulation of elraglusib, allowing a Phase 1/2 study in advanced solid tumors, including metastatic melanoma, NSCLC, colorectal and pancreatic cancers, with initiation planned for the second half of 2026.
The company is shifting its elraglusib program from an IV to an oral formulation after a Phase 2 trial in metastatic pancreatic ductal adenocarcinoma showed improved overall survival when IV elraglusib was added to gemcitabine plus nab-paclitaxel. Actuate also highlights nonclinical and early clinical data supporting use in RAS-driven cancers and rare pediatric cancers such as Ewing sarcoma and neuroblastoma, and notes potential value from a future pediatric Priority Review Voucher.
At the same time, the exhibits reiterate that Actuate’s financial condition raises substantial doubt about its ability to continue as a going concern and that it needs additional capital to fund operations beyond mid-2026, which could force delays or reductions in its development programs if financing is not obtained.